Pfizer has pulled the plug on an early-stage PD-L1 program as it looks to refine its cancer strategy after a series of encouraging readouts and high-value deals in recent months. The asset, dubbed PF-08046037, was being evaluated in a Phase 1 study, which combined the drug with sasanlimab, another investigational cancer therapy. Pfizer was testing the doublet against a variety of advanced or metastatic cancers, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and head and

April 21, 2026 -- Circulating white blood cells called neutrophils are some of the immune system's first responders. Their numbers shoot up during infection and inflammation, shifting the ratio of neutrophils to other types of immune cells in the blood. This ratio, called the neutrophil to lymphocyte ratio (NLR), is easily obtained from a complete blood cell count, which is used by clinicians to diagnose infection and other immune conditions. Now, a new study led by researchers at NYU Langone

ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual Meeting ADCE-D01, a first-in-class uPARAP targeted ADC, granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) First patient dosed in Phase I trial of ADCE-B05, an ADC directed against an undisclosed first-in-cla

April 17, 2026 -- The Parker Institute for Cancer Immunotherapy (PICI), today announced that research and expertise from across its network will be showcased at the American Association for Cancer Research Annual Meeting, taking place April 17- 22 in San Diego, California. PICI leaders, investigators, and collaborators are contributing to nearly 100 posters, presentations, and discussions throughout the program - demonstrating the depth and breadth of the network's contributions to the field of

A New Hope for Patients with Advanced Gastric and Pancreatic Cancers April 9, 2026 -- A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients. The therapy, known as satri-cel (CT041), is the world's first CAR-T

April 3, 2026 -- OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and expression solutions, today announced a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. This collaboration brings together OneCyte's proprietary single-cell platform for high-throughput, high-sensitivity, and high-speed clone selection with Kemp Protein

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant’s InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or intolerant to standard treatments. This a

Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic arthritis Data includes real-world evidence of minimal disease activity and clinical long-term safety outcomes of upadacitinib in atopic dermatitis, as well as investigational Phase 3 data for vitiligo and alopecia areata March 27, 2026 -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 20

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline wi

Kalohexis' lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists March 19, 2026 -- Endevica Bio, a privately-held company developing first-in-class synthetic peptidomimetics, toda